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Abstract Chronic obstructive pulmonary disease (COPD) is a disease state characterized by air-flow limitation that is 
not fully reversible, and progressive lung function decline. In Italy an estimated 2.6 million men and women have COPD, 
and the disease causes around I8 000 deaths each year: In addition to mortality, morbidity from COPD results in 
substantial use of secondary healthcare resources.The burden of COPD in Italy may be due to the underdiagnosis of the 
disease by healthcare professionals, particularly in the early stages of the disease, and a lack of awareness among physicians 
of recommended treatment practices. In an attempt to address the need for information on the burden of COPD, a large- 
scale international survey, Confronting COPD in North America and Europe, assessed clinical outcomes, use of healthcare 
resources and loss of productivity in the workplace, and the economic cost of this disease in Italy and six other countries. 
In Italy the economic analysis of the survey data showed that the mean annual cost of COPD to the healthcare system 
was E I26 I .25 per patient. Indirect costs were estimated at e47.29 per patient, bringing the societal cost of the disease 
to E 1308.54 per patientThree-quarters of the direct per patient cost of COPD in Italy were accounted for by inpatient 
hospitalizations (~Z963. IO), suggesting that interventions aimed at preventing exacerbations could alleviate the burden of 
COPD in Italy. The high impact of COPD on the Italian healthcare system is also likely to be a consequence of the 
underdiagnosis and undertreatment of the disease, suggesting that costs may be reduced by increasing the utilization of 
spirometry as a diagnostic tool, and improving physician adherence to treatment guidelines. Patients with severe COPD 
and other comorbidities showed higher costs (e6366 and E I86 I, respectively) than patients with mild disease (E44 I) or 
no comorbidities (e IO2 I), underlying the importance of smoking cessation interventions to prevent disease progression. 
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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
disease state characterized by airflow limitation that is 
not fully reversible, and progressive lung function decline. 
The main risk factor for the development of COPD is a 
long-term history of smoking behaviour (I). In Italy, 
epidemiological studies have attempted to measure the 
prevalence of respiratory symptoms and COPD among 
the general population (2-5). The results showed a 
higher prevalence of respiratory symptoms and diseases 
among smokers than non-smokers, with the prevalence 
of COPD increasing with age. One large-scale cross- 
sectional epidemiological survey conducted in Northern 
Italy found that 6% of men aged 46-55 years and I I %  of 
men aged 55-65 years had been diagnosed with chronic 
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bronchitis, and 2% of men above the age of 45 years had 
been diagnosed with emphysema (2). Using smoking 
rates to estimate the prevalence of diagnosed and 
undiagnosed COPD, the results of a disease model 
suggested that 2.6 million men and women aged 
45-70 years in Italy have the disease (6). 
National statistics show that COPD causes 
considerable mortality in Italy (7). Over  18000 deaths 
from chronic bronchitis and emphysema were recorded 
in 1999, equivalent to 50% of the total number of deaths 
from respiratory conditions during this year. In addition 
to mortality, morbidity from COPD results in substantial 
use of secondary healthcare resources. In 1997, COPD 
was the seventh leading cause of hospitalization in Italy 
(ranking fifth if surgical procedures are excluded) (8). 
There were over I million inpatient bed days (mean 
length of stay IO.6 days) for chronic bronchitis, 
compared with just 142000 inpatient bed days for 
asthma (mean stay of 5.7 days). 
The burden of COPD in Italy may be due to the 
underdiagnosis of the disease by healthcare 
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professionals, particularly in the early stages of the 
disease. Although spirometry is recommended as the 
gold standard diagnostic test for COPD, it is 
underutilized in primary care practice. Among the 
reasons for this are poor accessibility to spirometers, 
which only tend to be available in the hospital setting, and 
limited prescribing of lung function tests in general 
practice. Furthermore, some patients are reluctant to 
bear their part of the cost of spirometry. These factors 
may delay contact with a healthcare professional for the 
diagnosis of respiratory symptoms. When spirometry is 
used, physicians may not be fully familiar with the nature 
of the results and their interpretation. The 
underdiagnosis of COPD leads to undertreatment, 
resulting in the sub-optimal management of the disease. 
Even when COPD is diagnosed, there may be a lack of 
awareness among physicians of recommended treatment 
practices, and treatment tends to vary from guideline 
recommendations. This is likely to result in poor 
symptom control and further use of healthcare services. 
The need for improved management of COPD in Italy 
may be highlighted by raising awareness of the burden of 
disease on the patient, healthcare system and society. 
Aside from data on prevalence, mortality and use of 
hospital resources arising from COPD, there is a lack of 
detailed information on the impact of the disease in Italy. 
This is also the case in other countries, as few studies 
have attempted to quantify the costs of the disease to 
society. In an attempt to address the need for 
information on the burden of COPD, a large-scale 
international survey, Confronting COPD in North America 
and Europe, interviewed patients and physicians to collect 
data on clinical outcomes, use of healthcare resources 
and loss of productivity in the workplace. The direct, 
indirect and total societal costs of COPD were 
calculated from the survey data.The clinical results of the 
survey revealed that COPD was associated with high 
levels of morbidity and disability (9). This paper reports 
the results of the health economic analysis of the 
Confronting COPD survey in Italy. 
METHODS 
Survey details 
The methodology used in the economic analysis of the 
Confronting COPD survey is described in detail 
elsewhere (IO). Briefly, responses to a telephone 
interview survey of patients from Italy, Canada, France, 
Germany, the Netherlands, Spain, the U.K. and the U.S.A. 
were used to collect information on COPD-related 
hospitalizations, emergency room visits, primary care 
consultations, treatment, and laboratory tests, over a 
12-month period. In all countries except Germany, 
healthcare resource utilization data were used to 
calculate the mean direct cost of COPD per patient, and 
information on time lost from work in patients with 
COPD was used to calculate the indirect cost of the 
disease. Direct and indirect costs were summed to give 
an estimate of the mean per patient cost of COPD to 
society. Finally, a sub-analysis of costs was conducted for 
patient groups stratified by disease severity, sex, smoking 
status, comorbidity and education level. 
Cost calculations 
To calculate the direct and indirect costs of COPD, unit 
costs were applied to measures of healthcare resource 
utilization and lost productivity, as shown in Table I .The 
unit costs of an antibiotic course, chest X-ray, 
computerized tomography (CT) scan, and electro- 
cardiogram (ECG) received during a hospital stay were 
included in the unit cost of an inpatient hospitalization. 
Unit costs of work loss due to COPD were applied in 
patients below the standard age of retirement in Italy 
(65 years in men, 60 years in women). 
RESULTS 
Patient demographics and clinical 
characteristics 
A summary of the patient sample enrolled in the Italian 
survey is shown in Table 2. Patients had a mean age of 
64years (range 45-97years), and 30% of the sample 
were female. Almost all the patients had a previous 
smoking history (99.8%), and half of the patients were 
smokers at the time of the survey; 90% of patients had 
been diagnosed with chronic bronchitis, emphysema or 
COPD, and the remaining patients had chronic bronchitis 
on the basis of symptom criteria (persistent coughing 
with phlegm or sputum production for at least 2 years). 
The majority of patients considered themselves to have 
mild or moderate COPD, but more than a quarter of 
patients reported that their symptoms were poorly or 
not at all controlled with current medication regimens. 
Comorbidity was reported by two-fifths of patients, 
most commonly kidney problems (19%) heart disease 
(6%) and hypertension (6%). 
Healthcare resource utilization 
Three-fifths (59%) of the patients in the Italian survey 
sample said that they usually visited their primary care 
practitioner (PCP) for COPD treatment, with an 
estimated I359 visits in the previous I2 months 
(Table 3). Most of these visits were by prior arrangement 
(reported by 40% of patients) (Fig. I). Unscheduled PCP 
visits were reported by 6% of the survey sample, with a 
maximum of lOvisits per patient in the past year.Two- 
fifths (41%) of the patients were under the care of a 
specialist for their condition, and 19% of patients had 
visited a respiratory specialist at least once in the last I2 
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FIGURE I. Percentage of patients reporting category of healthcare resource use during the I2 months prior to the survey. 
months. Although only 4% of patients (n=l5) required 
unscheduled specialist visits in the past year (Fig. I), 19% 
of the total number of specialist visits were unscheduled 
(Table 3). More than one-fifth of patients recalled having 
a hospital stay for COPD, and I I% of patients were 
hospitalized during the I2 months prior to the survey. 
Over I30 inpatient stays were reported (Table 3). 
Around 6% of patients visited the emergency room for 
treatment (Fig. I). 
One-third (35%) of the patients in the survey were 
currently receiving prescription medication, and the 
three most commonly prescribed classes of drug were 
inhaled corticosteroids, theophylline, and short-acting 
&-agonists (Fig. 2).Two-fifths of patients had a nebulizer 
for the administration of bronchodilator medication. 
Only 56% of patients in the Italian sample had received 
an influenza vaccination. Almost half of the patients 
surveyed received antibiotics for the treatment of 
respiratory infections during the previous year, with a 
maximum of 20 courses taken by any one patient 
(Table 4). A small minority of patients used home oxygen 
therapy, with a total of 8695 days of use (equivalent to a 
mean of 263.5 days use for each patient using oxygen). 
An estimated 666 laboratory investigations were 
conducted during the l2-month survey period (mean 
I .7 tests per patient). Around half of the patients with 
COPD reported a chest X-ray or an ECG, and a quarter 
of patients reported a test of blood oxygen levels 
(Table 5). One in eight patients reported a CT or 
magnetic resonance imaging (MRI) scan. 
Lost productivity 
Just under two-fifths (37%) of patients in the Italian 
sample were under the age of retirement. A number of 
patients reported that they were completely prevented 
from working (I I %), limited in their ability to work (6%) 
or missed days from work (4%) due to COPD-related 
illness or disability. An estimated I58 days of work were 
lost (mean 0.40, maximum 30 days). In addition, 9% of 
patients reported that their caregiver had missed work 
as a result of COPD, with a total of 62 days of work 
absence (mean 0-I 5, maximum I2 days) during the past 
year. 
Direct costs 
When unit costs were applied to the data on healthcare 
resource utilization, the annual cost of COPD to the 
healthcare system was estimated at e 1261.25 per 
patient. Mean per patient costs for each healthcare 
resource measure are shown in Table 6.The highest per 
patient cost of any individual healthcare resource was for 
inpatient hospitalizations (e963. IO), which accounted 
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FIGURE 2. Use of prescribed medication for COPD 
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for three-quarters of the total direct costs of COPD. In 
contrast, treatment for COPD accounted for only one- 
sixth of direct costs, with less than 6% of costs due to 
PCP or specialist visits (Fig. 3). 
Indirect and societal costs 
When the unit cost of lost productivity was applied to 
patient work absence, the indirect cost of COPD was 
estimated at e47.29 per patient.Adding this cost to the 
direct cost of COPD gave an estimated societal cost of 
G  1308.54 per patient. 
Costs sub-analysis 
The total societal costs of COPD from the Italian sample 
were analysed in terms of disease severity, sex, smoking 
status, comorbidity, and education level (separate 
analyses for direct and indirect costs are not presented, 
as 96.4% of total costs were direct costs). The results 
showed that patients with severe COPD, either self- 
perceived or assessed using the Medical Research 
Council (MRC) Dyspnoea Scale, were associated with 
higher per patient societal costs than patients with mild 
or moderate COPD (Fig. 4). Costs were also higher in 
males than in females, in former smokers than in current 
smokers, in patients with comorbidity compared with no 
comorbidity, and in educated patients compared with 
patients with no education beyond basic schooling 
(Table 7). 
DISCUSSION 
The Confronting COPD survey assessed healthcare 
resource utilization and lost productivity in patients who 
had been diagnosed with COPD, or were identified with 
chronic bronchitis on the basis of symptoms (persistent 
cough with sputum production for at least 2years). 
Estimates of direct and indirect costs were also made 
from the survey data. 
In Italy, the annual cost of COPD to the healthcare 
system, including hospital visits, healthcare professional 
contacts, treatment and diagnostic tests, was over c I26 I 
per patient. The direct cost of COPD accounted for 
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FIGURE 3. Percentage breakdown of annual direct costs of COPD for Confrontmg COPD tn Italy 
almost all of the cost of COPD to society, with less than 
4% of total costs resulting from patient work loss. 
However, the estimate of indirect costs in this survey is 
likely to be an underestimate, as lost productivity in the 
caregivers of patients with COPD was not included in 
the analysis. 
Three-quarters of the direct per patient cost of 
COPD in Italy were accounted for by inpatient 
hospitalizations. These figures tend to confirm the first 
Italian study on this topic, which showed that the cost of 
COPD was higher than for bronchial asthma due to the 
higher cost of hospitalizations (I I). One of the main 
causes of hospitalization in patients with COPD is an 
acute exacerbation of symptoms, which is typically 
caused by respiratory infection. The frequency of 
exacerbations in the Italian sample was highlighted by the 
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FIGURE 4. Annual societal cost of COPD by disease severity. 
proportion of patients (46%) who received antibiotics 
for the treatment of infections.These results suggest that 
the burden of COPD on the patient and the healthcare 
system could be alleviated by the use of interventions 
that may reduce the risk of exacerbations. Treatment 
guidelines recommend influenza vaccination as an 
important strategy for the prevention of exacerbations 
in patients diagnosed with COPD, yet only 56% of 
patients in the Italian sample had been vaccinated in the 
year prior to the survey. Medications that may act upon 
the underlying inflammatory processes of the disease 
may reduce the frequency and severity of exacerbations 
and could have an important role to play in reducing the 
burden of COPD in this country. 
The sub-optimal management of chronic symptoms in 
patients with COPD may also contribute to the burden 
of COPD in Italy. Poor symptom control was reported 
by 28% of patients in the survey. Inadequate symptom 
management may be a consequence of the 
underdiagnosis and undertreatment of patients with 
COPD: one in ten patients in the survey had not been 
diagnosed, and only one-third of patients were currently 
being treated with regular prescription medication 
(demonstrating that even diagnosed patients were not all 
receiving treatment for the disease). These results 
suggest that there may be a need for better diagnosis of 
COPD (e.g. using spirometry) and improved adherence 
to treatment guidelines, to ensure that all patients with 
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COPD have their symptoms managed with appropriate 
medications. 
Previous studies of the burden of COPD in other 
countries have shown that associated costs rise with 
disease severity (I 2-l 3). The results of Confronting 
COPD in Italy showed that the annual societal costs of 
the disease were I4 times higher per patient with severe 
COPD (as assessed using the MRC Dyspnoea Scale) than 
mild COPD.Therefore, interventions that may delay the 
progression of COPD to the severe stages may reduce 
the economic impact of the disease in Italy. High priority 
should be given to encouraging patients to stop smoking 
at the early stages of COPD, as smoking cessation is the 
only intervention proven to reduce the decline in lung 
function that is associated with the progression this 
disesase. Smoking cessation may also help to reduce the 
risk of comorbidity in patients with COPD: another 
factor shown by the survey to be associated with high 
healthcare costs in COPD in Italy. 
CONCLUSION 
COPD is a disease associated with substantial direct costs 
in Italy. Much of the cost of COPD calculated in the survey 
was due to inpatient hospitalizations, suggesting that 
interventions designed to reduce the risk of exacerbations 
could alleviate the burden of COPD in this country.The 
high impact of COPD on the healthcare system is also a 
likely consequence of the underdiagnosis and under- 
treatment of the disease, suggesting that costs may be 
reduced by increasing the utilization of spirometry as a 
diagnostic tool and improving physician adherence to 
treatment guidelines. Smoking cessation interventions 
could also play an important role in lowering the 
substantial costs associated with severe COPD and 
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